Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Tax Provisions: 2012-2025

Historic Tax Provisions for Ani Pharmaceuticals (ANIP) over the last 13 years, with Sep 2025 value amounting to $7.2 million.

  • Ani Pharmaceuticals' Tax Provisions rose 198.20% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 743.43%. This contributed to the annual value of -$3.7 million for FY2024, which is 437.60% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Tax Provisions of $7.2 million as of Q3 2025, which was up 260.00% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Tax Provisions peaked at $7.2 million during Q3 2025, and registered a low of -$7.3 million during Q3 2024.
  • For the 3-year period, Ani Pharmaceuticals' Tax Provisions averaged around $1.1 million, with its median value being $1.2 million (2023).
  • In the last 5 years, Ani Pharmaceuticals' Tax Provisions plummeted by 57,900.00% in 2022 and then surged by 881.82% in 2024.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Tax Provisions stood at -$6.7 million in 2021, then spiked by 78.13% to -$1.5 million in 2022, then soared by 85.84% to -$208,000 in 2023, then slumped by 1,575.96% to -$3.5 million in 2024, then skyrocketed by 198.20% to $7.2 million in 2025.
  • Its Tax Provisions stands at $7.2 million for Q3 2025, versus $2.0 million for Q2 2025 and $4.3 million for Q1 2025.